Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > My How Time Flies When You Are Having Fun!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(90)
•••
Comment by TheTruth1234on May 04, 2023 2:09pm
102 Views
Post# 35430666

RE:RE:RE:RE:RE:RE:My How Time Flies When You Are Having Fun!

RE:RE:RE:RE:RE:RE:My How Time Flies When You Are Having Fun!
Boomskid wrote: I know a hell of a lot more than what you might think I know, DM. 

About the CEOs telling me the truth about xB3, Bioasis is still touting it. It makes no difference whether the corporate presentation has 2 pages or 50 pages dedicated to xB3, the statement is the same. And the xB3 deals with Chiesi, J&J, Prothena, XOMA, etc, are still on the books. 

If xB3 has failed, then Bioasis is lying.

As I posted long ago about calling the company to get the story, remember what Mark Twain said in his short story, "What Stumped the Bluejays":
 
"Animals talk to each other, of course. There can be no question about that; but I suppose there are very few people who can understand them. I never knew but one man who could. I knew he could, however, because he told me so himself."

jd



""know a hell of a lot more than what you might think I know, DM""


Yeah. Sure.  That is exactly why you invested ypur entire life savings into Bioasis and are now broke living in aTrailer!



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities